| 纯度 | > 70 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | APOA5 |
| Uniprot No | Q96H31 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-366aa |
| 氨基酸序列 | RKGFWDYFSQ TSGDKGRVEQ IHQQKMAREP ATLKDSLEQD LNNMNKFLEK LRPLSGSEAP RLPQDPVGMR RQLQEELEEV KARLQPYMAE AHELVGWNLE GLRQQLKPYT MDLMEQVALR VQELQEQLRV VGEDTKAQLL GGVDEAWALL QGLQSRVVHH TGRFKELFHP YAESLVSGIG RHVQELHRSV APHAPASPAR LSRCVQVLSR KLTLKAKALH ARIQQNLDQL REELSRAFAG TGTEEGAGPD PQMLSEEVRQ RLQAFRQDTY LQIAAFTRAI DQETEEVQQQ LAPPPPGHSA FAPEFQQTDS GKVLSKLQAR LDDLWEDITH SLHDQGHSHL GDPAAADYKD DDDK |
| 预测分子量 | 40 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **APOA5重组蛋白** 的3篇参考文献示例(文献信息为虚拟概括，仅供参考)：
---
1. **文献名称**: *"Recombinant human APOA5 enhances lipoprotein lipase activity and ameliorates hypertriglyceridemia in mice"*
**作者**: Smith JL, et al.
**摘要**: 研究通过重组技术表达人源APOA5蛋白，证实其通过激活脂蛋白脂肪酶(LPL)显著降低高脂血症小鼠的血清甘油三酯水平，揭示了APOA5在脂代谢调控中的关键作用。
2. **文献名称**: *"Structural and functional characterization of recombinant APOA5: Role in triglyceride-rich lipoprotein metabolism"*
**作者**: Tanaka M, et al.
**摘要**: 通过X射线晶体学解析重组APOA5的三维结构，发现其通过特异性结合脂蛋白颗粒表面调控甘油三酯水解，为遗传性高甘油三酯血症的治疗提供分子机制依据。
3. **文献名称**: *"Recombinant APOA5 mitigates atherosclerosis via promoting cholesterol efflux in macrophages"*
**作者**: Wang Y, et al.
**摘要**: 利用重组APOA5处理动脉粥样硬化模型小鼠，证明其通过增强巨噬细胞胆固醇外流能力减少斑块形成，提示APOA5在抗动脉粥样硬化中的潜在治疗价值。
---
**注**：以上文献信息为示例，实际研究中建议通过 **PubMed** 或 **Web of Science** 检索关键词“APOA5 recombinant protein”获取真实文献。
Apolipoprotein A-V (APOA5) is a key regulator of triglyceride (TG) metabolism, primarily synthesized in the liver and circulating in plasma at low concentrations. Encoded by the APOA5 gene on chromosome 11. this 366-amino-acid protein plays a critical role in modulating plasma TG levels through interactions with lipoproteins and lipoprotein lipase (LPL). Genetic studies have linked APOA5 variants to hypertriglyceridemia, cardiovascular diseases, and metabolic disorders, highlighting its clinical relevance.
Recombinant APOA5 protein is engineered to study its structure-function relationships and therapeutic potential. Produced using expression systems like E. coli or mammalian cells, the recombinant form allows researchers to investigate its lipid-binding properties, LPL activation mechanisms, and role in lipid particle remodeling. Unlike native APOA5. which is challenging to isolate due to low abundance, recombinant versions offer scalability and purity for experimental consistency. Advanced purification techniques, including affinity chromatography and tag-based systems, ensure high-quality protein for biochemical assays, cell culture studies, and animal models.
Current research focuses on leveraging recombinant APOA5 to develop TG-lowering therapies, diagnostic biomarkers, and gene-editing strategies. However, challenges persist in mimicking post-translational modifications and maintaining functional stability in vivo. Despite these hurdles, APOA5 recombinant proteins remain vital tools for unraveling lipid metabolism pathways and advancing precision medicine approaches for dyslipidemia-related conditions.
×
